Summary
Chemotherapy with mitomycin C, ifosfamide and cisplatin (MIC) is reported to produce responses of 56% and 69% in inoperable non-small-cell lung cancer (NSCLC) [1,2]. We evaluated the regimen in 45 similar patients who received up to six courses of 6 mg/m2 mitomycin C, 3 g/m2 ifosfamide, and 50 mg/m2 cisplatin every 3 weeks. In all, 18 patients had limited disease (LD) and 27 had extensive disease (ED). A total of 18 patients responded (40%), 9/18 with LD and 9/27 with ED; there were 4 complete responders. The median duration of response was 25 weeks, and median survival was 32 weeks (range, 2–96 weeks). Toxicity was moderate. Nausea and vomiting were controlled with i.v. dexamethasone and high-dose metoclopramide. Other toxicities included myelosuppression and alopecia. This study confirms that MIC is one of the most active regimens for treatment of NSCLC, with acceptable toxicity.
References
Bakowski MT, Creach JC (1983) Chemotherapy of non small cell lung cancer. A reappraisal and a look to the future. Cancer Treat Rev 10: 159
Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM (1988) Mitomycin, ifosfamide and cisplatin in non small cell lung cancer: treatment good enough to compare. Br J Cancer 58: 359–361
Giron CG, Ordonez A, Jalon JI, Baron MG (1987) Combination chemotherapy with ifosfamide, mitomycin and cisplatin in advanced non small cell lung cancer. Cancer Treat Rep 71 (9): 851–853
Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S (1986) A randomized trial of the four most active regimens for metastatic non small cell lung cancer. J Clin Oncol 4 (1): 14–22
World Health Organisation (1979) Handbook for reporting results of cancer Treatment. Offset Publication 48, WHO, Geneva
Author information
Authors and Affiliations
Additional information
Supported by the Cancer Research Campaign
Rights and permissions
About this article
Cite this article
Currie, D.C., Miles, D.W., Drake, J.S. et al. Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer. Cancer Chemother. Pharmacol. 25, 380–381 (1990). https://doi.org/10.1007/BF00686243
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686243